Proactive assessment of patient reported outcomes in patients with ovarian cancer.
Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Amit M. Oza(Ontario Institute for Cancer Research), David Valcárcel(Vall d'Hebron Hospital Universitari), Lawrence Kasherman(The University of Sydney), Stéphanie Lheureux(Princess Margaret Cancer Centre), Luís Manso(Research Institute Hospital 12 de Octubre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Ana Oaknin(Hebron University), Eva Ciruelos(Hospital Universitario 12 De Octubre), Laura Lema(Hospital Universitario 12 De Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre), Manuel Alva Bianchi(Research Institute Hospital 12 de Octubre), José Manuel Estrada Lorenzo(Research Institute Hospital 12 de Octubre)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k